Table 2.
Achievement of clinical and treatment targets comparing trial groups over time
| Time | Experimental Intervention Number (%) | Standard Care Control Number (%) | P | |
|---|---|---|---|---|
| BP ≤130/80 | Baseline | 139/236 (59) | 101/235 (43) | 0.03a |
| 12 months | 134/218 (61.5) | 100/218 (45.9) | 0.47b | |
| 24 months | 81/128 (63.2) | 64/136 (47) | 0.76c | |
| LDL <2.5 mmol/L | Baseline | 99/230 (43) | 81/220 (36.8) | 0.41a |
| 12 months | 97/206 (47.1) | 99/214 (46.3) | <0.001b | |
| 24 months | 78/122 (63.9) | 76/128 (59.4) | 0.74c | |
| On RAAS blocker | Baseline | 165/236 (70) | 156/235 (66) | 0.49a |
| 12 months | 165/219 (75) | 146/220 (66) | 0.92b | |
| 24 months | 102/130 (78) | 92/140 (66) | 0.06c | |
| Hba1c ≤7.0% in diabetics | Baseline | 38/68 (55.9) | 36/74 (48.6) | 0.58a |
| 12 months | 50/70 (71.4) | 52/77 (67.5) | <0.001b | |
| 24 months | 40/49 (81.6) | 43/52 (82.7) | 0.76c | |
| Hemoglobin ≥105 g/L | Baseline | 229/235 (97.4) | 232/234 (99.1) | 0.81a |
| 12 months | 208/214 (97.2) | 203/214 (94.8) | 0.07b | |
| 24 months | 125/128 (97.7) | 130/136 (95.6) | 0.64c | |
| Iron saturation ≥0.2 | Baseline | 169/225 (75.1) | 160/226 (70.8) | 0.28a |
| 12 months | 154/210 (73.3) | 155/210 (73.8) | 0.24b | |
| 24 months | 95/128 (74.2) | 95/124 (76.6) | 0.31c | |
| Serum phosphate <1.8 mmol/L | Baseline | 235/235 (100) | 233/233 (100) | NA |
| 12 months | 211/211 (100) | 218/218 (100) | NA | |
| 24 months | 125/126 (99.2) | 126/127 (99.2) | NA | |
| Bicarbonate ≥22 mmol/L | Baseline | 225/234 (96.1) | 230/234 (98.3) | 0.18a |
| 12 months | 209/215 (97.2) | 212/214 (99.1) | 0.68b | |
| 24 months | 124/127 (97.6) | 124/127 (97.6) | 0.37c |
All of the P values are from generalized estimating equations. NA, statistical analysis is not applicable as target was almost uniformly met. RAAS, renin-angiotensin-aldosterone.
a
Comparison at baseline.
b
Comparison over time within group.
c
Comparison between groups over time adjusted for baseline.